Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04200911 · ClinicalTrials.gov registry record · Early Phase 1
Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway
A Early Phase 1 study of Alzheimer Disease and Cognitive Impairment, Mild, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04200911 is a Early Phase 1 study of Alzheimer Disease and Cognitive Impairment, Mild that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 10 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04200911, a Early Phase 1 study of Alzheimer Disease and Cognitive Impairment, Mild, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluation of central nervous system penetration of orally administered Rapamune (RAPA) in older adults with Mild Cognitive Impairment (MCI) or early Alzheimer's disease (AD) and investigate associated safety, tolerability, target engagement, cognition, and functional status as initial proof-of-concept study
Conditions Studied
Interventions
- DRUG Rapamune
Study Locations (1)
Texas
- UTHSA McDermott Clinical Sciences Building - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2022-01-13 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04200911
The ClinicalTrials.gov registry entry for NCT04200911 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Rapamune is the first listed.
NCT04200911 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04200911 about?
NCT04200911 is a clinical study titled "Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway". Evaluation of central nervous system penetration of orally administered Rapamune (RAPA) in older adults with Mild Cognitive Impairment (MCI) or early Alzheimer's disease (AD) and investigate associated safety, tolerability, target engagement, cognition, and functional status as initial proof-of-conc...
What is the current status of trial NCT04200911?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2020-06-01. Estimated completion is 2022-01-13.
What conditions does trial NCT04200911 study?
This clinical trial studies the following conditions: Alzheimer Disease, Cognitive Impairment, Mild.
What interventions are being tested in trial NCT04200911?
The interventions under investigation include: Rapamune (DRUG).
Who is sponsoring clinical trial NCT04200911?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04200911 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
Neuroinflammation Imaging in AD
RECRUITING · Early Phase 1
-
Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease
RECRUITING · Early Phase 1
-
Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia
RECRUITING · Early Phase 1
-
Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease
RECRUITING · Early Phase 1
-
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.